Connect with us

Business insider

New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years

New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients withatopic dermatitis as young as 6 years N…

Published

on

New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients withatopic dermatitis as young as 6 years

  • Nearly 30 data presentations at AAD and ESPD across clinical and real-world settings, including the impact of Dupixent on disease measures in uncontrolled moderate-to-severe atopic dermatitis
  • Late-breaking Phase 2 data for rilzabrutinib, an investigational therapy for pemphigus vulgaris, a rare, debilitating autoimmune disease, to be presented at AAD

PARIS – April 23, 2021 – New analyses from Dupixent® (dupilumab) trials evaluated infection incidence reduction and reinforced the need for no laboratory monitoring in patients six years and older with moderate-to-severe atopic dermatitis. Additional analyses evaluated response rates across a broad population, and the impact of Dupixent on disease extent and severity, quality of life (QoL), and itch. These and other data from real-world settings and clinical trials, including the Dupixent open-label extension (OLE) trials, will be presented at the American Academy of Dermatology (AAD VMX 2021), April 23-25, and at the 20th European Society for Pediatric Dermatology Annual Meeting (ESPD 2021), May 12-14.

“The depth and breadth of data being presented at AAD and ESPD support the use of Dupixent in adults, adolescents and childrensix years and older, addressing multiple critical disease measures such as itch, disease extent and severity,and certain skin infections,” said Naimish Patel, M.D. Head of Global Development in Immunology and Inflammation at Sanofi. “In addition, our expanded efforts in research and development in the immunology space, includingrilzabrutinib, underscores our long-term commitment to addressing serious dermatological conditions with unmet patient needs.”

Results from a subgroup analysis of the Phase 2 study evaluating rilzabrutinib, an investigational oral Bruton’s tyrosine kinase inhibitor (BTKi), for the treatment of pemphigus vulgaris (PV), include the rates of control of disease activity in patients with moderate-to-severe disease. These data will be presented as a late-breaking abstract oral presentation at AAD VMX 2021. PV is a rare, debilitating autoimmune disease that causes blistering of the skin and mucus membranes.

Abstracts to be presented at AAD VMX 2021

Pediatric efficacy and QoL data for Dupixent

  • Abstract 27350: Dupilumab Improves Eczema Area and Severity Index Regional Scores Across All Anatomical Regions in Children Aged 6–11 Years with Severe Atopic Dermatitis (AD), Amy S. Paller
  • Abstract 27375: Dupilumab Provides Early and Sustained Improvement of Sleep Disturbance in Children ≥ 6 Years With Severe Atopic Dermatitis (AD) and Adolescents With Moderate-to-Severe AD, Amy S. Paller
  • Abstract 27389: Rapid and Sustained Improvement in Itch in Children Aged 6–11 Years With Severe Atopic Dermatitis (AD) Treated With Dupilumab: Analysis From the LIBERTY AD PEDS Phase 3 Trial, Amy S. Paller
  • Abstract 27394: Dupilumab Provides Clinically Meaningful Improvement in Atopic Dermatitis (AD) Signs, Symptoms, and Quality of Life in Children With Severe AD: Results From the LIBERTY AD PEDS Phase 3 Clinical Trial, Amy S. Paller
  • Abstract 27406: Dupilumab Improves Signs and Symptoms of Severe Atopic Dermatitis in Children Aged 6–11 Years With and Without Comorbid Asthma, Mark Boguniewicz
  • Abstract 27406: Dupilumab Treatment Improves Health-Related Quality of Life in Children Aged ≥6 to <12 Years With Severe Atopic Dermatitis, Alan Irvine

Adult efficacy data for Dupixent

  • Abstract 26839: Dupilumab With Topical Corticosteroids Results in Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across All Anatomic Regions Over 52 Weeks, Andrew Blauvelt
  • Abstract 27571: Dupilumab Provides Clinically Meaningful Responses in Adults With Moderate-To-Severe Atopic Dermatitis (AD): Results From LIBERTY AD CHRONOS Study, Jonathan I. Silverberg

Long-term data from DupixentOLE studies, up to three years in adults and up to one year in adolescents (aged 12-17 years) and children (aged 6-11 years) with moderate-to-severe atopic dermatitis.

  • Abstract 26313: Efficacy and Safety of Dupilumab for up to 1 Year in a Phase 3 Open-Label Extension (OLE) Trial (LIBERTY AD PED-OLE) in Adolescents With Uncontrolled, Moderate-To-Severe Atopic Dermatitis (AD), Andrew Blauvelt
  • Abstract 26875: 52-Week Laboratory Safety Findings From an Open-Label Extension (OLE) Study of Dupilumab in Adolescent Patients With Atopic Dermatitis (LIBERTY AD PED-OLE), Michael J. Cork
  • Abstract 26880: Long-Term Efficacy and Safety Data for Dupilumab in a Phase 3, Open-Label Extension Trial (LIBERTY AD PED-OLE) in Patients Aged ≥6 to <12 Years With Uncontrolled, Moderate-to-Severe Atopic Dermatitis (AD), Michael J. Cork
  • Abstract 27419: Laboratory Safety of Long-Term Dupilumab Treatment in Adults With Moderate-to-Severe Atopic Dermatitis: Open-Label Extension (OLE) Study, Andrew Blauvelt
  • Abstract 27424: Infections in Adults with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Long-Term Data from an Open-Label Extension (OLE) Study, Andrew Blauvelt

Real-world data for Dupixent

  • Abstract 27434: Early Trends of Disease Improvement in Adult Patients With Atopic Dermatitis Treated With Dupilumab: Real-World Data From the PROSE Registry, Jerry Bagel

Abstracts presenting data on the burden and impact of atopic dermatitis include:

  • Abstract 27430: Worldwide Survey Shows That Atopic Dermatitis Is Associated with a High Disease Burden in Children, Stephan Weidinger
  • Abstract 27473: Worldwide Survey Shows That Atopic Dermatitis in Children is Associated with a Negative Impact on Their Families, Sebastien Barbarot
  • Abstract 28081: Strategies to Improve Quality of Atopic Dermatitis Care in the North America: Results from the Atopic Dermatitis Quality of Care (ADQoC) Initiative, Peter Lio

A late-breaking abstract oral presentation for rilzabrutinib:

  • Treatment with Rilzabrutinib Results in Rapid and Significant Decrease in Steroid Use and Improved Quality of Life in Patients with Chronic Relapsing Pemphigus: BELIEVE Phase 2 Study, Dedee F. Murrell

Abstracts to be presented at ESPD 2021

Abstracts related to data evaluating efficacy, safety and impact on health-related quality of life of Dupixent include:

Efficacy data

  • ESPD21-0326: Dupilumab Provides Clinically Meaningful Improvement in Atopic Dermatitis (AD) Signs, Symptoms, and Quality of Life in Children With Severe AD, Stephan Weidinger
  • ESPD21-0330: Dupilumab Improves EASI Regional Scores Across All Anatomical Regions in Children Aged ≥6–<12 Years With Severe Atopic Dermatitis, Michael J. Cork
  • ESPD21-0331: Rapid Itch Improvement in Children With Severe Atopic Dermatitis Treated With Dupilumab: A Phase 3 Subset Analysis, Gil Yosipovitch
  • ESPD21-0332: Dupilumab Significantly Improves Signs and Symptoms of Atopic Dermatitis Assessed by SCORAD in Children Aged ≥6 to <12 Years, Sebastien Barbarot
  • ESPD21-0334: Dupilumab Treatment Improves Health-Related Quality of Life in Children Aged ≥6 to <12 Years With Severe Atopic Dermatitis, Alan Irvine
  • ESPD21-0340: Dupilumab Improved Itch in Children Aged 6–11 Years With Severe Atopic Dermatitis: Analysis from the LIBERTY AD PEDS Trial, Amy S. Paller
  • ESPD21-0341: Dupilumab Treatment Improves Sleep in Children Aged ≥6 to <12 Years With Severe Atopic Dermatitis, Amy S. Paller

Long-term data

  • ESPD21-0335: Long-Term Efficacy and Safety of Dupilumab in a Phase 3, Open-Label Extension Trial in Children With Uncontrolled, Moderate-to-Severe Atopic Dermatitis, Michael J. Cork

Safety data

  • ESPD21-0200: Increased Incidence of Conjunctivitis With Dupilumab Treatment in Adolescents Appears to be Specific to Atopic Dermatitis, Marjolein De Bruin-Weller
  • ESPD21-0308: Laboratory Safety of Dupilumab in Children Aged ≥6–<12 Years With Severe Atopic Dermatitis: Results From a Phase 3 Trial, Andreas Wollenberg

Results from a qualitative survey on the impact of atopic dermatitis

  • ESPD21-0322: AD-GAP: A Global, Cross-sectional, Qualitative Survey of Children/Adolescents Aged 6−17 Years With Moderate-to-Severe Atopic Dermatitis, Their Carers, and Physicians, Stephan Weidinger

About Dupixent
Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. IL-4 and IL-13 are key and central drivers of the type 2 inflammation that plays a major role in atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP) and eosinophilic esophagitis.

Dupixent is approved in the U.S. to treat patients aged 6 years and older with moderate-to-severe atopic dermatitis that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies; for use with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid dependent asthma in patients aged 12 years and older whose asthma is not controlled with their current asthma medicines; and for use with other medicines for the maintenance treatment of CRSwNP in adults whose disease is not controlled.

Outside of the U.S., Dupixent is approved for specific patients with moderate-to-severe atopic dermatitis and certain patients with asthma in a number of other countries around the world, including those in the EU and Japan. Dupixent is also approved in the EU and Japan to treat certain adults with severe CRSwNP. Across all approved indications globally, more than 260,000 patients have been treated with Dupixent.

Dupilumab Development Program
To date, dupilumab has been studied in more than 10,000 patients across 50 clinical trials in various chronic diseases driven in part by type 2 inflammation.

In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven in part by type 2 inflammation or other allergic processes, including pediatric asthma (6 to 11 years of age, Phase 3), chronic obstructive pulmonary disease with evidence of type 2 inflammation (Phase 3), pediatric atopic dermatitis (6 months to 5 years of age, Phase 3), eosinophilic esophagitis (Phase 3), bullous pemphigoid (Phase 3), prurigo nodularis (Phase 3), chronic spontaneous urticaria (Phase 3), chronic inducible urticaria-cold (Phase 3), chronic rhinosinusitis without nasal polyposis (Phase 3), allergic fungal rhinosinusitis (Phase 3) and food allergies (Phase 2). The use of dupilumab in these settings is currently under clinical investigation and its safety and efficacy have not been fully evaluated by any regulatory authority. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement.

About Rilzabrutinib
Rilzabrutinib is an oral, reversible covalent, Bruton’s tyrosine kinase (BTK) inhibitor being investigated for the treatment of immune mediated diseases. BTK is involved in innate and adaptive immune responses and is a signaling molecule in immune mediated diseases. Rilzabrutinib pre-clinical data demonstrate an ability to help block inflammatory immune cells, eliminate autoantibody destructive signaling, and prevent new autoantibody production without depleting B cells. Rilzabrutinib has the potential to target the underlying disease pathogenesis and has not been shown to alter platelet aggregation. The clinical significance of this data is under investigation. Rilzabrutinib is currently under clinical investigation and its safety and efficacy have not been evaluated by any regulatory authority.

Editor’s Note: Rilzabrutinib has been granted orphan drug designation by the FDA for both pemphigus vulgaris (and from the European Commission for the treatment of pemphigus vulgaris and pemphigus foliaceus) and for its investigational use in immune thrombocytopenia (ITP). In November 2020, we announced that rilzabrutinib was granted FDA Fast Track Designation for ITP.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Media Relations Contacts
Sally Bain
Tel.: +1 (781) 264-1091
[email protected]
Investor Relations – Paris
Eva Schaefer-Jansen
Arnaud Delepine

Investor Relations – North America
Felix Lauscher
Fara Berkowitz
Suzanne Greco

IR main line:
Tel.: +33 (0)1 53 77 45 45
[email protected]

https://www.sanofi.com/en/investors/contactSanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2020. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

  • Press Release

Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post.

“The depth and breadth of data being presented at AAD and ESPD support the use of Dupixent in adults, adolescents and childrensix years and older, addressing multiple critical disease measures such as itch, disease extent and severity,and certain skin infections,” said Naimish Patel, M.D. Head of Global Development in Immunology and Inflammation at Sanofi. “In addition, our expanded efforts in research and development in the immunology space, includingrilzabrutinib, underscores our long-term commitment to addressing serious dermatological conditions with unmet patient needs.”

Source: https://markets.businessinsider.com/news/stocks/new-dupixent-dupilumab-analyses-reinforce-long-term-safety-and-efficacy-profile-in-patients-with-atopic-dermatitis-as-young-as-6-years-1030338905

new-dupixent®-(dupilumab)-analyses-reinforce-long-term-safety-and-efficacy-profile-in-patients-with-atopic-dermatitis-as-young-as-6-years

Business insider

A 29-year-old crypto billionaire who’s made millions from digital-currency arbitrage shares 2 tips for investors looking to get started in trading- and explains why ether is unlikely to surpass…

Sam Bankman-Fried, the founder of FTX and Alameda Research. FTX Sam Bankman-Fried became a billionaire through leveraging a cryptocurrency arb…

Published

on

Sam Bankman-Fried, founder of FTX and Alameda ResearchSam Bankman-Fried, the founder of FTX and Alameda Research.

FTX

  • Sam Bankman-Fried became a billionaire through leveraging a cryptocurrency arbitrage strategy.
  • Bankman-Fried now runs a leading derivative cryptocurrency exchange, FTX.
  • He shares his tips for crypto trading and his outlook on bitcoin vs. ether.
  • See more stories on Insider’s business page.

Sam Bankman-Fried is a cofounder of the cryptocurrency exchange FTX and a legend in the world of crypto trading.

His crypto arbitrage strategy netted him 10% daily returns on million-dollar crypto trades, helping him to accumulate a net worth that placed him on Forbes’ list of cryptocurrency billionaires at just 29 years old.

Although Bankman-Fried’s wealth provides him with more than enough money to retire comfortably on a faraway island, he instead dedicates his time to building the ultimate cryptocurrency exchange for traders.

His goal is to create an alternative to the “s—show exchanges” that existed when he was trading in 2017 and 2018, Bankman-Fried said in an interview with Insider.

“We thought the odds are pretty high that we would fail on the exchange because we thought we would just never get any users and that would be that, but it seemed high enough upside that it was worth going for anyway,” Bankman-Fried said.

Within two years, FTX went from relatively unknown to one of the top five derivative-trading exchanges, with more than $400 billion in monthly trading volume in April.

FTX changed the trading game by enabling the management of collateral through a single wallet. This meant traders could trade anything on FTX through one margin wallet, as long as they had enough collateral to meet their total position size.

“It’s one of the rare times that you find a change, which both simplifies the product and makes it more powerful,” Bankman-Fried said.

Some might assume that, by simplifying the collateralization process, FTX would face more risk when it comes to liquidations, a process that occurs when traders don’t have enough collateral to support their position.

Yet when a recent flash crash caused a 17% drop in the value of bitcoin and liquidations worth $9.3 billion on April 17, FTX fared better than most.

The platform is designed to discourage mass liquidations by limiting the size of the positions traders can put on with really high leverage and having an engine that liquidates only as much as it needs to, Bankman-Fried said.

Total liquidations graph from ByBtTotal liquidations graph from ByBt.

ByBt

Crypto trading tips

There is fierce competition from other traders in the cryptocurrency market, and breaking in is hard, Bankman-Fried said. “It’s not a super forgiving place to try and get into,” he said.

First, get to know the market by learning from the experts. Bankman-Fried spent several years learning his craft at the trading firm Jane Street.

Second, try to figure out what edge you have, such as great technology or a good instinct for the direction of the market, he said.

“I think one of the interesting things is the blurring line between trader and an investor in crypto,” Bankman-Fried said.

Bankman-Fried’s approach to trading is evolving. He has formed an appreciation for how great crypto investors have been able to operate in different market environments and is spending more time thinking about strategies that set him up well for future cycles, something he said he didn’t have great instincts for previously.

“Often, a lot of the upside is in the cases where the bull market stays. That’s where you should be focusing a lot of your thoughts because that’s where it matters the most what you do,” Bankman-Fried said. “But with the caveat that you have to make sure that you don’t f— yourself over if there’s a temporary bear market, that you don’t put yourself in a position where you can’t survive that.”

Bitcoin vs. ether

The most-traded cryptocurrency is bitcoin, which has a market capitalization near $1 trillion. In recent weeks, the Ethereum blockchain’s native currency, ether, has arguably made its case as a challenger to bitcoin, as the currency has surged more than 100% in price since the start of April with a market capitalization of $450 billion.

Bitcoin’s 93% gain so far this year has been dwarfed by ether’s 450% increase in that time. The Ethereum network houses a variety of decentralized finance applications, including nonfungible tokens, or NFTs, which have been all the rage among artists and celebrities. The multiple uses of the network, plus the fact that its carbon footprint is considerably smaller than that of bitcoin, have burnished ether’s popularity.

Bankman-Fried said he would be surprised to see ether overtake bitcoin, considering bitcoin has the massive advantage of being the first and agreed-upon default cryptocurrency, which is worth a lot.

For all its diverse uses, Ethereum has its own issues, such as serious scaling challenges, which are going to hold it back, Bankman-Fried said.

“It’s hard for me to see ether displacing bitcoin, although I could be wrong there,” he said.

Sam Bankman-Fried is a cofounder of the cryptocurrency exchange FTX and a legend in the world of crypto trading.

Source: https://markets.businessinsider.com/currencies/news/crypto-trading-tips-ethereum-outlook-young-billionaire-sam-bankman-fried-2021-5-1030415441

a-29-year-old-crypto-billionaire-who's-made-millions-from-digital-currency-arbitrage-shares-2-tips-for-investors-looking-to-get-started-in-trading--and-explains-why-ether-is-unlikely-to-surpass...

Continue Reading

Business insider

Dogecoin plummets during Elon Musk’s ‘Saturday Night Live’ hosting gig as Robinhood experiences issues

Miley Cyrus was the musical guest on "SNL," while Elon Musk hosted. NBC/Getty Images The value of the cryptocurrency Dogecoin fell dur…

Published

on

Miley Cyrus Elon Musk SNLMiley Cyrus was the musical guest on “SNL,” while Elon Musk hosted.

NBC/Getty Images

  • The value of the cryptocurrency Dogecoin fell during Elon Musk’s episode of “Saturday Night Live.”
  • At the same time, Robinhood tweeted that its app was experiencing difficulties with trading.
  • Robinhood declined to comment on whether the difficulty was due to changes in trading during “SNL.”
  • See more stories on Insider’s business page.

Dogecoin’s stock price fell during billionaire Elon Musk’s appearance on “Saturday Night Live” on May 9.

The cryptocurrency, which started as a joke in 2013 but recently gained popularity with Musk’s vocal support, fell to about $0.5 around 12:30 a.m. early Sunday morning, according to Coindesk, but the price steadily picked up as the show went on.

Musk touted Dogecoin during his appearance on the show’s “Weekend Update” sketch, saying the cryptocurrency would “take over the world” and calling himself the “Dogefather.”

At the same time, Robinhood, the multi-billion dollar stock trading app, said the platform was experiencing issues with crypto-trading.

“Update: We’re currently experiencing issues with crypto trading,” Robinhood tweeted during Musk’s performance. “We’re working to resolve this as soon as possible.”

-Robinhood Help (@AskRobinhood) May 9, 2021

Robinhood told Insider that the platform’s crypto-trading was “back up and running” about 30 minutes after it first reported difficulties. Robinhood declined to comment on whether the issues were tied to the “SNL” performance.

-Robinhood Help (@AskRobinhood) May 9, 2021

Dogecoin was originated in 2013 by IBM software engineer Billy Markus and Adobe software engineer Jackson Palmer.

This year, Dogecoin has had more than a 12,000% year-to-date rally, and spiked the week prior to Musk’s hosting gig on “Saturday Night Live.” The Reddit group Wall Street Bets, which cheered an unlikely rally of GameStop stock earlier this year, has also championed Dogecoin.

Source: https://markets.businessinsider.com/currencies/news/dogecoin-drop-robinhood-down-elon-musk-snl-episode-2021-5-1030405331

dogecoin-plummets-during-elon-musk's-'saturday-night-live'-hosting-gig-as-robinhood-experiences-issues

Continue Reading

Business insider

Spark Networks Announces Conference Call to Discuss First Quarter 2021 Results

BERLIN, May 5, 2021 /PRNewswire/ — Spark Networks SE (NYSE: LOV), one of the world’s leading online dating companies, announced today that the co…

Published

on

BERLIN, May 5, 2021 /PRNewswire/ — Spark Networks SE (NYSE: LOV), one of the world’s leading online dating companies, announced today that the company will hold a conference call to discuss First Quarter 2021 financial results on Monday, May 17, 2021 at 10:00 am ET.

(PRNewsfoto/Spark Networks SE)

Dial-in Information
Call Title: Spark Networks SE First Quarter 2021 Earnings Conference Call
Toll Free: 1-877-705-6003
Toll/International: 1-201-493-6725
Germany Toll-Free: 0 800-182-0040

In addition, the Company will host a webcast of the call which will be accessible in the Investor Relations section of the Company’s website at https://investor.spark.net/investor-relations/home. A replay will begin approximately three hours after completion of the call and run until May 31, 2021.

Replay Information
Toll Free: 1-844-512-2921
Toll/International: 1-412-317-6671
Replay Pin Number: 13719604

About Spark Networks SE:
Spark Networks SE is America’s second largest dating company, listed on the New York Stock Exchange American under the ticker symbol “LOV,” with headquarters in Berlin, Germany, and offices in New York and Utah. The Company’s widening portfolio of premium and freemium dating apps include Zoosk, EliteSingles, Christian Mingle, Jdate, JSwipe, SilverSingles and eDarling, among others. Spark Networks SE in its current form is the result of the merger between Affinitas GmbH and Spark Networks, Inc. in 2017 and the addition of Zoosk, Inc. in 2019. Spark Networks has approximately one million monthly paying subscribers globally.

Safe Harbor Statement:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, statements involving known and unknown risks, uncertainties, and other factors that may cause Spark Networks’ performance or achievements to be materially different from those of any expected future results, performance, or achievements. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Written words, such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates,” and variations thereof, or the use of future tense, identify forward-looking statements. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future. There are a number of factors that could cause actual results and developments to differ materially, including, but not limited to, the risk that the benefits from the acquisition of Zoosk, Inc. may not be fully realized or may take longer to realize than expected; risks related to the degree of competition in the markets in which Spark Networks operates; risks related to the ability of Spark Networks to retain and hire key personnel; the timing and market acceptance of new products introduced by Spark Networks’ competitors; Spark Networks’ ability to identify potential acquisitions; Spark Networks’ ability to comply with new and evolving regulations relating to data protection and data privacy; general competition and price measures in the market place; risks related to the duration and severity of Covid-19 and its impact on Spark Networks’ business; and general economic conditions. Additional factors that could cause actual results to differ are discussed under the heading “Risk Factors” in Spark Networks’ Annual Report on Form 20-F for the year ended December 31, 2019 and in other sections of Spark Networks’ filings with the Securities and Exchange Commission (“SEC”), and in Spark Networks’ other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to Spark Networks as of the date hereof, and Spark Networks assumes no obligation to update any forward-looking statement except as required by law.

Contact:
Christopher Camarra
Vice President of Investor Relations
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/spark-networks-announces-conference-call-to-discuss-first-quarter-2021-results-301284505.html

SOURCE Spark Networks SE

Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post.

Source: https://markets.businessinsider.com/news/stocks/spark-networks-announces-conference-call-to-discuss-first-quarter-2021-results-1030391112

spark-networks-announces-conference-call-to-discuss-first-quarter-2021-results

Continue Reading

Title

Techcrunch4 hours ago

Maybe SPACs were a bad idea after all – TechCrunch

Welcome back to The TechCrunch Exchange, a weekly startups-and-markets newsletter for your weekend enjoyment.

Techcrunch6 hours ago

Leveling the playing field – TechCrunch

There is an atmosphere of collaboration, not competition, around the creation of hardware for gamers within the assistive technology community.

ZDNET9 hours ago

A useful Android privacy feature that most people have never heard of

Android has a useful hidden feature that the iPhone doesn't.

Coinpedia12 hours ago

Polygon (Matic) Price Continues to Rise Amidst Market Correction!

The MATIC price forecasts are positive as a token supporting such a critical feature right now. After the Ethereum scaling

Reuters14 hours ago

Chip shortage to hit about 100,000 Mazda vehicles in 2021

Mazda Motor Corp (7261.T) said on Friday it expects a semiconductor crunch to affect around 100,000 of the Japanese automaker's...

Blockchain news1 day ago

Ethereum Gas Fees Surge to a Monthly High, Supply on Exchanges Continues to Decline

Ethereum's total fees has hit a monthly high of 746.026 ETH.

CNBC2 days ago

Disney misses on subscriber expectations, parks revenue still hurt by Covid restrictions

Disney+ had been bolstering the company's success as it was losing out on business from Covid restrictions, but it seems...

Entrepreneur2 days ago

Let Go of Assumptions and Reset Your Brand Mindset

Many small businesses make the mistake of trying to please everyone. You can't, so stop trying.

Cointelegraph2 days ago

Polkadot-centric derivatives exchange raises $6.4M in seed funding

The successful private investment round highlights growing conviction in the Polkadot ecosystem.

Ventureburn2 days ago

Hack the Normal winning innovators announced

The Hack the Normal online hackathon has announced the winning innovations in each of the event's categories for this year's...

Review

    Select language

    Trending